The company believes its ultrasensitive immunoassay technology is well-suited to pharma research.
NEW YORK (GenomeWeb) – Fresh off a $74 million initial public offering, Quanterix is looking to make immediate inroads in the biotech and pharma research space with longer-term plans to move into diagnostics and health monitoring.
The company believes its ultrasensitive immunoassay technology is well-suited to pharma research where it can allow scientists to measure biomarkers undetectable by current methods and improve upon the data quality of existing assays, said Kevin Hrusovsky, Quanterix’s executive chairman and CEO.
The recent IPO, Hrusovsky said, was in large part done to help generate business from these firms.
